Back to top
more

Assembly Biosciences (ASMB)

(Delayed Data from NSDQ)

$12.65 USD

12.65
29,385

-0.71 (-5.31%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $12.39 -0.26 (-2.06%) 7:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (174 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

TEVA Shares Rise on Broad Support for Opioids Settlement

by Zacks Equity Research

With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.

After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for August 4th

by Zacks Equity Research

PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.

New Strong Buy Stocks for August 4th

by Zacks Equity Research

ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.

Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)

by Zacks Equity Research

Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Assembly Biosciences (ASMB) Q1 Earnings Expected to Decline

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 88.46% and 437.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Assembly Biosciences (ASMB) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 733.33% and 28.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Assembly Biosciences (ASMB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How Assembly Biosciences (ASMB) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

by Zacks Equity Research

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

Why Assembly Biosciences (ASMB) Stock Might be a Great Pick

by Zacks Equity Research

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Assembly Biosciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Assembly Biosciences

Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

by Zacks Equity Research

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

by Zacks Equity Research

Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.